EurekaMag.com logo
+ Translate

Evaluation of a neutron boost in head and neck cancer results of the randomized radiation therapy and oncology group trial 78 08


, : Evaluation of a neutron boost in head and neck cancer results of the randomized radiation therapy and oncology group trial 78 08. American Journal of Clinical Oncology 9(1): 61-66

Patients with untreated squamous cell cancer of the head and neck region were randomized to receive either a boost of 25-30 Gy using photon-beam irradiation (photons) or an equivalent boost using neutron-beam irradiation (neutrons). All patients received an initial 45-50 Gy of wide-field photon irradiation. A total of 57 patients was evaluable on the neutron arm and 58 were evaluable on the photon arm. The proportion of patients with complete responses was 60 and 64% on the neutron and photon arms, respectively. The locally disease-free proportion at 2 years was estimated to be 20 and 31%, and the 2-year survival was estimated to be 32 and 41%, respectively. These differences are not statistically significant. There was a higher rate of severe complications on the neutron arm, 16 versus 7%. Thus, there was no evidence that a neutron boost produces better initial tumor clearance, local tumor control, or survival than photon boost, and it may produce more complications.

(PDF 0-2 workdays service)

Accession: 005395314

Submit PDF Full Text: Here


Submit PDF Full Text

No spam - Every submission is manually reviewed

Due to poor quality, we do not accept files from Researchgate

Submitted PDF Full Texts will always be free for everyone
(We only charge for PDFs that we need to acquire)

Select a PDF file:
Close
Close

Related references

Maor, M.H.; Schoenfeld, D.A.; Hendrickson, F.R.; Davis, L.W.; Laramore, G.E.; Thomas, F.J.; Pajak, T.F., 1986: Evaluation of a neutron boost in head and neck cancer. Results of the randomized RTOG trial 78-08. Patients with untreated squamous cell cancer of the head and neck region were randomized to receive either a boost of 25-30 Gy using photon-beam irradiation (photons) or an equivalent boost using neutron-beam irradiation (neutrons). All patients r...

Thomas, F.J.; Krall, J.; Hendrickson, F.; Griffin, T.W.; Saxton, J.P.; Parker, R.G.; Davis, L.W., 1989: Evaluation of neutron irradiation of pancreatic cancer. Results of a randomized Radiation Therapy Oncology Group clinical trial. Between 1980-84, the Radiation Therapy Oncology Group conducted a trial in patients with untreated, unresectable localized carcinomas of the pancreas. Patients were randomly chosen to receive either 6,400 cGy with photons, the equivalent dose with...

Griffin T.W.; Davis R.; Hendrickson F.R.; Maor M.H.; Laramore G.E., 1984: Fast neutron radiation therapy for unresectable squamous cell carcinomas of the head and neck the results of a randomized radiation therapy and oncology group study. Forty patients with advanced, unresectable squamous cell carcinomas of the head and neck were entered on a prospective, randomized study comparing fast neutron radiation therapy with conventional photon radiation therapy. Twenty-six patients were...

Garden, A.S.; Harris, J.; Trotti, A.; Jones, C.U.; Carrascosa, L.; Cheng, J.D.; Spencer, S.S.; Forastiere, A.; Weber, R.S.; Ang, K.Kian., 2008: Long-term results of concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: a phase II trial of the radiation therapy oncology group (RTOG 99-14). Purpose: The feasibility of combining concomitant boost-accelerated radiation regimen (AFX-C) with cisplatin was previously demonstrated in this Phase II trial. This article reports the long-term toxicity, relapse patterns, and survival in patien...

Anonymous, 2007: Results of radiation therapy oncology group 97-03 - A randomized phase II trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck: Long-term results and late toxicities

Garden, A.S.; Harris, J.; Vokes, E.E.; Forastiere, A.A.; Ridge, J.A.; Jones, C.; Horwitz, E.M.; Glisson, B.S.; Nabell, L.; Cooper, J.S.; Demas, W.; Gore, E., 2004: Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck. To define further the role of concurrent chemoradiotherapy for patients with advanced squamous carcinoma of the head and neck. The Radiation Therapy Oncology Group developed this three-arm randomized phase II trial. Patients with stage III or IV s...

Ang, K.Kian.; Harris, J.; Garden, A.S.; Trotti, A.; Jones, C.U.; Carrascosa, L.; Cheng, J.D.; Spencer, S.S.; Forastiere, A.; Weber, R.S., 2005: Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: radiation therapy oncology group phase II trial 99-14. To investigate the feasibility of combining concomitant boost accelerated radiation regimen (AFX-C) with cisplatin and to assess its toxicity and the relapse pattern and survival in patients with advanced head and neck carcinoma (HNC). Between Apr...

Hoffman, K.E.; Pugh, S.L.; James, J.L.; Scarantino, C.; Movsas, B.; Valicenti, R.K.; Fortin, A.; Pollock, J.; Kim, H.; Brachman, D.G.; Berk, L.B.; Bruner, D.Watkins.; Kachnic, L.A., 2014: The impact of concurrent granulocyte-macrophage colony-stimulating factor on quality of life in head and neck cancer patients: results of the randomized, placebo-controlled Radiation Therapy Oncology Group 9901 trial. The Radiation Therapy Oncology Group (RTOG) conducted a randomized, placebo-controlled trial evaluating the efficacy of GM-CSF in reducing mucosal injury and symptom burden from curative radiotherapy for head and neck (H&N) cancer. Eligible pa...

Machtay, M.; Pajak, T.F.; Suntharalingam, M.; Shenouda, G.; Hershock, D.; Stripp, D.C.; Cmelak, A.J.; Schulsinger, A.; Fu, K.K., 2007: Radiotherapy with or without erythropoietin for anemic patients with head and neck cancer: a randomized trial of the Radiation Therapy Oncology Group (RTOG 99-03). Purpose: To determine whether the addition of recombinant human erythropoietin (Epo) could improve the outcomes of anemic patients receiving definitive radiotherapy for squamous cell carcinoma of the head and neck (SCCHN).Methods and Materials: El...

Shenouda, G.; Zhang, Q.; Ang, K.Kian.; Machtay, M.; Parliament, M.B.; Hershock, D.; Suntharalingam, M.; Lin, A.; Rotman, M.; Nabid, A.; Hong, S.; Shehata, S.; Cmelak, A.J.; Sultanem, K.; Le, Q-Thu., 2015: Long-term results of radiation therapy oncology group 9903: a randomized phase 3 trial to assess the effect of erythropoietin on local-regional control in anemic patients treated with radiation therapy for squamous cell carcinoma of the head and neck. This paper reports long-term results of RTOG 9903, to determine whether the addition of erythropoietin (EPO) would improve the outcomes of radiation therapy (RT) in mildly to moderately anemic patients with head and neck squamous cell carcinoma (...